Skip to main content
Erschienen in: Drugs & Aging 1/2018

01.01.2018 | Original Research Article

The EURO-FORTA (Fit fOR The Aged) List: International Consensus Validation of a Clinical Tool for Improved Drug Treatment in Older People

verfasst von: Farhad Pazan, Christel Weiss, Martin Wehling, FORTA

Erschienen in: Drugs & Aging | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Drug treatment of older people is still potentially inappropriate in many cases as multimorbidity and related polypharmacy are highly prevalent. To increase the quality of drug treatment in older people, the FORTA (Fit fOR The Aged) List (first version 2012) was developed in a Delphi consensus procedure and updated (FORTA2015) by 21 experts from Germany and Austria. It has been validated in a randomized, controlled, prospective trial demonstrating significant improvement in the quality of drug treatment and clinical endpoints (VALFORTA).

Methods

Based on these results, Delphi consensus validations (two rounds) of country/region-specific FORTA Lists were conducted in the UK/Ireland, France, Poland, Italy, Spain, the Nordic countries and The Netherlands. An algorithm based on geriatric/pharmacologic expertise, publications and professional position was used to find experts in the field.

Results

Forty-seven experts agreed to participate in the Delphi process (return rate of 97.9%). For each country/region, the overall mean consensus coefficient (deviation from the initiator proposal) was > 0.9. FORTA Lists from six countries/regions with a minimum of four participating experts (excluding The Netherlands) plus the original FORTA List were collated into the EURO-FORTA List containing 264 items in 26 main indication groups. Two drugs had to be added to the proposed items, as proposed by at least four countries/regions; none had to be removed.

Conclusion

This project produced seven new country/region-specific FORTA Lists, as well as the overarching EURO-FORTA List showing a high consensual level based on a broader expert base. EURO-FORTA should help to spread the FORTA approach and improve geriatric pharmacotherapy internationally.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
3.
Zurück zum Zitat Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13:57–65.CrossRefPubMed Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13:57–65.CrossRefPubMed
4.
Zurück zum Zitat Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380:37–43.CrossRefPubMed Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380:37–43.CrossRefPubMed
5.
Zurück zum Zitat Mc Namara KP, Breken BD, Alzubaidi HAT, et al. Health professional perspectives on the management of multimorbidity and polypharmacy for older patients in Australia. Age Ageing. 2017;46:291–9.PubMed Mc Namara KP, Breken BD, Alzubaidi HAT, et al. Health professional perspectives on the management of multimorbidity and polypharmacy for older patients in Australia. Age Ageing. 2017;46:291–9.PubMed
6.
Zurück zum Zitat Watts G. Why the exclusion of older people from clinical research must stop. BMJ. 2012;344:e3445.CrossRefPubMed Watts G. Why the exclusion of older people from clinical research must stop. BMJ. 2012;344:e3445.CrossRefPubMed
7.
Zurück zum Zitat Clegg A, Relton C, Young J, et al. Improving recruitment of older people to clinical trials: use of the cohort multiple randomised controlled trial design. Age Ageing. 2015;44:547–50.CrossRefPubMed Clegg A, Relton C, Young J, et al. Improving recruitment of older people to clinical trials: use of the cohort multiple randomised controlled trial design. Age Ageing. 2015;44:547–50.CrossRefPubMed
9.
10.
Zurück zum Zitat Wehling M. Guideline-driven polypharmacy in elderly, multimorbid patients is basically flawed: there are almost no guidelines for these patients. J Am Geriatr Soc. 2011;59:376–7.CrossRefPubMed Wehling M. Guideline-driven polypharmacy in elderly, multimorbid patients is basically flawed: there are almost no guidelines for these patients. J Am Geriatr Soc. 2011;59:376–7.CrossRefPubMed
11.
Zurück zum Zitat Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. Arch Intern Med. 1997;157:1531–6.CrossRefPubMed Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. Arch Intern Med. 1997;157:1531–6.CrossRefPubMed
12.
Zurück zum Zitat American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;2015(63):2227–46.CrossRef American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;2015(63):2227–46.CrossRef
13.
Zurück zum Zitat Page RL, Ruscin JM. The risk of adverse drug events and hospital-related morbidity and mortality among older adults with potentially inappropriate medication use. Am J Geriatr Pharmacother. 2006;4:297–305.CrossRefPubMed Page RL, Ruscin JM. The risk of adverse drug events and hospital-related morbidity and mortality among older adults with potentially inappropriate medication use. Am J Geriatr Pharmacother. 2006;4:297–305.CrossRefPubMed
14.
Zurück zum Zitat Cooper JA, Cadogan CA, Patterson SM, et al. Interventions to improve the appropriate use of polypharmacy in older people: a Cochrane systematic review. BMJ Open. 2015;5:e009235.CrossRefPubMedPubMedCentral Cooper JA, Cadogan CA, Patterson SM, et al. Interventions to improve the appropriate use of polypharmacy in older people: a Cochrane systematic review. BMJ Open. 2015;5:e009235.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Wehling M. Older people, a plethora of drugs, and drug list approaches: useful, efficacious, or a waste of time? J Am Med Dir Assoc. 2016;17:1073–5.CrossRefPubMed Wehling M. Older people, a plethora of drugs, and drug list approaches: useful, efficacious, or a waste of time? J Am Med Dir Assoc. 2016;17:1073–5.CrossRefPubMed
16.
Zurück zum Zitat Wehling M. Drug therapy in the elderly: too much or too little, what to do? A new assessment system: fit for the aged FORTA [in German]. Dtsch Med Wochenschr. 2008;133:2289–91.CrossRefPubMed Wehling M. Drug therapy in the elderly: too much or too little, what to do? A new assessment system: fit for the aged FORTA [in German]. Dtsch Med Wochenschr. 2008;133:2289–91.CrossRefPubMed
17.
Zurück zum Zitat Kuhn-Thiel AM, Weiss C, Wehling M. Consensus validation of the FORTA (Fit fOR The Aged) List: a clinical tool for increasing the appropriateness of pharmacotherapy in the elderly. Drugs Aging. 2014;31:131–40.CrossRefPubMed Kuhn-Thiel AM, Weiss C, Wehling M. Consensus validation of the FORTA (Fit fOR The Aged) List: a clinical tool for increasing the appropriateness of pharmacotherapy in the elderly. Drugs Aging. 2014;31:131–40.CrossRefPubMed
18.
Zurück zum Zitat Pazan F, Weiss C, Wehling M. The FORTA (Fit fOR The Aged) List 2015: update of a validated clinical tool for improved pharmacotherapy in the elderly. Drugs Aging. 2016;33:447–9.CrossRefPubMed Pazan F, Weiss C, Wehling M. The FORTA (Fit fOR The Aged) List 2015: update of a validated clinical tool for improved pharmacotherapy in the elderly. Drugs Aging. 2016;33:447–9.CrossRefPubMed
19.
Zurück zum Zitat Wehling M, Burkhardt H, Kuhn-Thiel A, et al. VALFORTA: a randomised trial to validate the FORTA (Fit fOR The Aged) classification. Age Ageing. 2016;45:262–7.CrossRefPubMed Wehling M, Burkhardt H, Kuhn-Thiel A, et al. VALFORTA: a randomised trial to validate the FORTA (Fit fOR The Aged) classification. Age Ageing. 2016;45:262–7.CrossRefPubMed
20.
Zurück zum Zitat Fialova D, Topinkova E, Gambassi G, et al. Potentially inappropriate medication use among elderly home care patients in Europe. JAMA. 2005;293:1348–58.CrossRefPubMed Fialova D, Topinkova E, Gambassi G, et al. Potentially inappropriate medication use among elderly home care patients in Europe. JAMA. 2005;293:1348–58.CrossRefPubMed
21.
Zurück zum Zitat Renom-Guiteras A, Meyer G, Thürmann PA. The EU(7)-PIM list: a list of potentially inappropriate medications for older people consented by experts from seven European countries. Eur J Clin Pharmacol. 2015;71:861–75.CrossRefPubMedPubMedCentral Renom-Guiteras A, Meyer G, Thürmann PA. The EU(7)-PIM list: a list of potentially inappropriate medications for older people consented by experts from seven European countries. Eur J Clin Pharmacol. 2015;71:861–75.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Pastor Cano J, Aranda Garcia A, Gascon Canovas JJ, et al. Spanish adaption of Beers criteria [in Spanish]. An Sist Sanit Navar. 2015;38:375–85.CrossRefPubMed Pastor Cano J, Aranda Garcia A, Gascon Canovas JJ, et al. Spanish adaption of Beers criteria [in Spanish]. An Sist Sanit Navar. 2015;38:375–85.CrossRefPubMed
27.
Zurück zum Zitat O’Mahony D, O’Sullivan D, Byrne S, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44:213–8.CrossRefPubMed O’Mahony D, O’Sullivan D, Byrne S, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44:213–8.CrossRefPubMed
28.
Zurück zum Zitat O’Connor MN, O’Sullivan D, Gallagher PF, et al. Prevention of hospital-acquired adverse drug reactions in older people using screening tool of older persons’ prescriptions and screening tool to alert to right treatment criteria: a cluster randomized controlled trial. J Am Geriatr Soc. 2016;64:1558–66.CrossRefPubMed O’Connor MN, O’Sullivan D, Gallagher PF, et al. Prevention of hospital-acquired adverse drug reactions in older people using screening tool of older persons’ prescriptions and screening tool to alert to right treatment criteria: a cluster randomized controlled trial. J Am Geriatr Soc. 2016;64:1558–66.CrossRefPubMed
Metadaten
Titel
The EURO-FORTA (Fit fOR The Aged) List: International Consensus Validation of a Clinical Tool for Improved Drug Treatment in Older People
verfasst von
Farhad Pazan
Christel Weiss
Martin Wehling
FORTA
Publikationsdatum
01.01.2018
Verlag
Springer International Publishing
Erschienen in
Drugs & Aging / Ausgabe 1/2018
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-017-0514-2

Weitere Artikel der Ausgabe 1/2018

Drugs & Aging 1/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.